Autoimmunity reviews最新文献

{"title":"Immunosenescence in autoimmune diseases","authors":"Huifang Hu ,&nbsp;Guangyue Zhang ,&nbsp;Tao Chen ,&nbsp;Yi Liu ,&nbsp;Liesu Meng ,&nbsp;Rikard Holmdahl ,&nbsp;Lunzhi Dai ,&nbsp;Yi Zhao","doi":"10.1016/j.autrev.2025.103805","DOIUrl":"10.1016/j.autrev.2025.103805","url":null,"abstract":"<div><div>Autoimmune diseases (AIDs) are a group of disorders in which the immune system mistakenly attacks the body's own tissues, characterized by the loss of tolerance to self-antigens and destruction of tissues. Aging is a natural process of physiological decline that also alters the immune system, a condition known as immunosenescence. During immunosenescence, the immune system undergoes various changes, including modifications and antigenicity of self-antigens, abnormalities in the quantity, phenotype, and function of lymphocytes and antibodies, as well as a narrowing of the B and T cell receptor repertoire, changes that may increase susceptibility to AIDs. Additionally, senescent immune cells and the senescence-associated secretory phenotype (SASP) contribute to target organ involvement in AIDs, exacerbating chronic inflammation and tissue damage. Mitochondrial dysfunction and metabolic imbalances in AIDs lead to the accumulation of senescent cells, which act as upstream drivers of immunosenescence. In this review, we summarize the bidirectional relationship between AIDs and immunosenescence, as well as its potential mechanisms. Therapeutic approaches targeting immunosenescence in AIDs remain at an early stage. Strategies aimed at resetting or reversing the aging immune system are expected to become a novel direction in the future.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 6","pages":"Article 103805"},"PeriodicalIF":9.2,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy, safety, and tolerability of antifibrotic agents in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis","authors":"Javier Narváez ,&nbsp;Martí Aguilar-Coll ,&nbsp;Montserrat Roig-Kim ,&nbsp;Judith Palacios-Olid ,&nbsp;Pol Maymó-Paituvi ,&nbsp;Laia de Daniel-Bisbe ,&nbsp;Dídac LLop","doi":"10.1016/j.autrev.2025.103804","DOIUrl":"10.1016/j.autrev.2025.103804","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the efficacy, safety, and tolerability of antifibrotic agents, nintedanib and pirfenidone, in the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).</div></div><div><h3>Methods</h3><div>A systematic literature review was conducted following PRISMA and MOOSE guidelines. Studies assessing nintedanib or pirfenidone in RA-ILD were included. A meta-analysis was performed using a random-effects model.</div></div><div><h3>Results</h3><div>Six studies (2 randomized controlled trials and 4 observational) involving 270 RA-ILD patients met the inclusion criteria. In total, 148 received nintedanib and 122 received pirfenidone. Nearly 70 % had a usual interstitial pneumonia pattern.</div><div>The pooled analysis revealed a mean FVC decline of −68.97 mL/year (95 % CI: −104.85 to −32.49; <em>p</em> &lt; 0.001) and a mean difference of 1.15 % (<em>p</em> = 0.33; after excluding influential studies: −0.28, <em>p</em> = 0.54). Their impact on %pDLCO has been less extensively evaluated, with a mean difference of −1.76 % (<em>p</em> = 0.36; after excluding influential studies: effect size −3.78, <em>p</em> &lt; 0.001). The changes in pulmonary function tests were comparable between nintedanib and pirfenidone.</div><div>Mortality rates ranged from 15 % to 35 %, with respiratory-specific mortality reported at 44 % to 100 %. Lung transplantation rates were 4–5 %.</div><div>Antifibrotic therapy was associated with a pooled adverse event (AE) rate of 73 % (95 % CI: 0.38–0.97; <em>p</em> &lt; 0.001), with gastrointestinal symptoms and hepatotoxicity being the most frequently reported. Treatment discontinuation due to AEs occurred in nearly 24 % of patients (95 % CI: 0.16–0.40; <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Antifibrotic agents demonstrated stabilization of %pFVC, with less robust evidence for %pDLCO in RA-ILD. Nearly one quarter of patients discontinued therapy due to AEs.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 6","pages":"Article 103804"},"PeriodicalIF":9.2,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress on estrogen and estrogen receptors in the occurrence and progression of autoimmune thyroid diseases","authors":"Jiewen Xie ,&nbsp;Jie Wang ,&nbsp;Xuejiao Cui","doi":"10.1016/j.autrev.2025.103803","DOIUrl":"10.1016/j.autrev.2025.103803","url":null,"abstract":"<div><div>Autoimmune thyroid disease (AITD) is a category of disease related to sex differences, with a significantly higher incidence in women than in men. In addition to X chromosome inactivation abnormalities, Estrogen and estrogen receptors may lead to the sex differences in AITD. Estrogen, estrogen receptors and estrogen receptor-mediated signaling pathways can affect the number and function of immune cells and the function of the thyroid to promote the development of AITD. This article describes the role of estrogen in regulating the composition ratio and the function of immune cells and the role of estrogen in promoting thyroid cell proliferation and thyroxine-binding protein and thyroid antibody production; the role of estrogen in stimulating the hypothalamus-pituitary–thyroid gland axis; and the role of estrogen and the estrogen receptor in the progression of AITD. These roles offer a new perspective for understanding the pathological mechanism of AITD and provide new targets for future therapeutic strategies.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 6","pages":"Article 103803"},"PeriodicalIF":9.2,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between breastfeeding and the risk of autoimmune diseases: A systematic review and meta-analysis","authors":"Wen-Jie Li ,&nbsp;Yue-Can Gao ,&nbsp;Xiao Hu ,&nbsp;Yu-Tong Tan ,&nbsp;Jia-Jun Deng ,&nbsp;Hai-Feng Pan ,&nbsp;Sha-Sha Tao","doi":"10.1016/j.autrev.2025.103801","DOIUrl":"10.1016/j.autrev.2025.103801","url":null,"abstract":"<div><h3>Objectives</h3><div>Previous studies on the association between breastfeeding and autoimmune diseases risk have yielded inconsistent findings. This study employed a systematic review and meta-analysis to explore the effect of breastfeeding and its duration against autoimmune diseases.</div></div><div><h3>Methods</h3><div>Six databases (PubMed, Web of Science, Embase, CINAHL, Cochrane Library, PsycINFO) were systematically searched from inception to September 24, 2024. Studies on the association between breastfeeding and rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ulcerative colitis (UC), Crohn's disease (CD), multiple sclerosis (MS) and type 1 diabetes mellitus (T1D) published within this period were included. Dichotomous outcome data from multiple studies were subjected to a random-effects meta-analysis using the Mantel-Haenszel method to estimate the pooled effect size. The Newcastle-Ottawa Scale was employed to evaluate quality.</div></div><div><h3>Results</h3><div>Of the 40 included studies (35 case-control studies and 5 cohort studies), 12 were stratified by the duration of breastfeeding. The combined effect showed a protective association between breastfeeding and a reduced risk of autoimmune diseases (OR = 0.80; 95 %CI: 0.72 to 0.89; <em>P</em> &lt; 0.001). This protective effect was significant for RA (OR = 0.66; 95 %CI: 0.46 to 0.93; <em>P</em> = 0.018), MS (OR = 0.78; 95 % CI: 0.63 to 0.98; <em>P</em> = 0.030) and T1D (OR = 0.80; 95 %CI: 0.66 to 0.98; <em>P</em> = 0.028), and was more pronounced with breastfeeding duration of at least four months (OR = 0.81; 95 %CI: 0.72 to 0.90; <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Breastfeeding provides an overall protective effect against autoimmune diseases and a significant protective effect on RA, MS and T1D. This protective effect appears stronger with breastfeeding duration of at least 4 months. These results highlight the necessity of promoting breastfeeding and supporting related policies to improve infant health.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 6","pages":"Article 103801"},"PeriodicalIF":9.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SLE patients with childhood-onset: A nation-wide population-based study","authors":"Alexandra Kachaner ,&nbsp;Arthur Mageau ,&nbsp;Jean-François Timsit ,&nbsp;Julien Rio ,&nbsp;Thomas Papo ,&nbsp;Karim Sacré","doi":"10.1016/j.autrev.2025.103802","DOIUrl":"10.1016/j.autrev.2025.103802","url":null,"abstract":"<div><div>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that typically affects women of childbearing age. Using a nationwide database, we aimed to assess the prevalence, main clinical features and outcomes of patients with childhood-onset SLE (cSLE). Data on all patients admitted to a French hospital between January 2011 and December 2020 with at least one ICD, 10th revision code for SLE were retrieved from the nationwide hospital medical information database. Individuals who developed systemic SLE before the age of 17 years were considered to have cSLE. Between 2011 and 2020, 36,791 unique SLE patients were hospitalised in France. Among them, 1030 individuals younger than 17 years (median [q1-q3] age 13.0 [11.0;15.0]) years, 81.9 % female) were identified as having cSLE. The prevalence of cSLE was 8.3 cases per 100,000 inhabitants. The main characteristics of cSLE did not differ by sex, except for a younger age of onset in boys. Older children have a higher incidence of lupus nephritis. Compared to adult-onset SLE, lupus nephritis and immune cytopenia were twice as frequent in cSLE. During a median follow-up of 7.1 [4.0–9.0] years, 539 (52.3 %) cSLE patients experienced at least one hospitalisation for an infection. A total of 6 patients (0.6 %) died. All of these deaths occurred during the hospitalisation in which the first lupus code was assigned. The prevalence of cSLE in France was 8.3 cases per 100,000 of the population. cSLE had a higher rate of renal nephritis and immune cytopenia than adult-onset SLE.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 6","pages":"Article 103802"},"PeriodicalIF":9.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143620515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of nutritional supplements and dietary interventions on rheumatoid arthritis: An umbrella review of meta-analyses of randomized controlled trials","authors":"Xue-Er Cheng ,&nbsp;Xiao Hu ,&nbsp;Jian Tang ,&nbsp;Qian-Qian Shi ,&nbsp;Sheng Li ,&nbsp;Yi-Sheng He ,&nbsp;Man Ge ,&nbsp;Jin-Hui Tao ,&nbsp;Peng Wang ,&nbsp;Hai-Feng Pan","doi":"10.1016/j.autrev.2025.103792","DOIUrl":"10.1016/j.autrev.2025.103792","url":null,"abstract":"<div><h3>Backgrounds</h3><div>The effects of nutritional supplements and dietary interventions on rheumatoid arthritis (RA) are still unclear.</div></div><div><h3>Objectives</h3><div>This study aimed to evaluate the impact of nutritional supplements and dietary interventions on RA patients.</div></div><div><h3>Methods</h3><div>The online databases of PubMed, Web of Science, Embase, and Cochrane Library were used to search the relevant literature from inception to December 2024. Meta-analyses with the inclusion of randomized controlled trials were selected to assess the effects of nutritional supplements or dietary interventions on RA. We accessed the methodological quality of included reviews using AMSTAR 2 and evaluated the quality of evidence for intervention effects using GRADE. Data synthesis and analysis were used by R 4.4.1 and STATA 17.</div></div><div><h3>Results</h3><div>A total of 14 articles were included, evaluating the effects of nutritional supplements and dietary interventions on RA management. Among these, 3 studies were rated as high quality, 6 as low quality, and 5 as critically low quality by AMSTAR2. The quality of evidence for intervention effects ranges from low to very low quality. The interventions assessed included polyunsaturated fatty acids (PUFAs), probiotics, total glucosides of paeony (TGP), anti-inflammatory diets (AIDs), and others. TGP was the only intervention to significantly reduce both the disease activity score and erythrocyte sedimentation rate, although the quality of evidence for these effects was low. Probiotics contributed to significant reductions in C-reactive protein and visual analogue scale scores, with both outcomes rated as low quality. PUFAs demonstrated significant improvements in tender joint count, swollen joint count, and morning stiffness, though, like the other interventions, these effects were also rated as low quality.</div></div><div><h3>Conclusion</h3><div>There was relatively strong evidence supporting that PUFAs, probiotics, TGP, and AIDs may show some benefits on RA. However, the low quality of evidence highlights the need for further high-quality research and real-world evidence to confirm their effectiveness.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 6","pages":"Article 103792"},"PeriodicalIF":9.2,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetics in autoimmune diseases: Unraveling the hidden regulators of immune dysregulation","authors":"Giacomo Bagni ,&nbsp;Edoardo Biancalana ,&nbsp;Emanuele Chiara ,&nbsp;Iole Costanzo ,&nbsp;Danilo Malandrino ,&nbsp;Elena Lastraioli ,&nbsp;Miki Palmerini ,&nbsp;Elena Silvestri ,&nbsp;Maria Letizia Urban ,&nbsp;Giacomo Emmi","doi":"10.1016/j.autrev.2025.103784","DOIUrl":"10.1016/j.autrev.2025.103784","url":null,"abstract":"<div><div>Autoimmune diseases result from complex interactions between genetic and environmental factors. Recent advances in epigenetic research shed light on the intricate regulatory mechanisms that contribute to the development and progression of such conditions.</div><div>The present review aims to explore the role of epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNAs, in the context of autoimmune diseases. We discuss the current understanding of epigenetic alterations associated with various autoimmune disorders, their impact on immune cell function, and their potential as innovative therapeutic targets. Additionally, we highlight the main future directions in the field of epigenetics in autoimmunity.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 6","pages":"Article 103784"},"PeriodicalIF":9.2,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143550254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of N-glycans in regulatory T cells in autoimmunity","authors":"Pedro Carneiro ,&nbsp;Manuel M. Vicente ,&nbsp;Maria Isabel Leite ,&nbsp;Maria Ernestina Santos ,&nbsp;Salomé S. Pinho ,&nbsp;Ângela Fernandes","doi":"10.1016/j.autrev.2025.103791","DOIUrl":"10.1016/j.autrev.2025.103791","url":null,"abstract":"<div><div>Regulatory T cells (Tregs) have a key role in the maintenance of immune tolerance and in the prevention of autoimmunity. Recent studies have shown an association between decreased Treg frequency and a deficient suppressive activity with the development of many autoimmune diseases. Although glycosylation, which consists in the addition of glycans to proteins and lipids on the cell surface, is recognized as a critical modification for T cell development and function, the relevance of glycans in Treg biology and activity, as well as their impact in the immunopathogenesis of autoimmune diseases, deserves more attention, as it is far from being fully understood. This review discusses the biological impact of <em>N</em>-glycans in Treg biology, highlighting their potential to uncover novel pathogenic mechanisms in autoimmunity and new targets for promising therapeutic approaches with clinical applications in autoimmune disease patients.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 6","pages":"Article 103791"},"PeriodicalIF":9.2,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143565995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The immune system in Hashimoto's thyroiditis: Updating the current state of knowledge on potential therapies and animal model construction","authors":"Ruixi Li,&nbsp;Ting He,&nbsp;Zhichao Xing,&nbsp;Li Mi,&nbsp;Anping Su,&nbsp;Wenshuang Wu","doi":"10.1016/j.autrev.2025.103783","DOIUrl":"10.1016/j.autrev.2025.103783","url":null,"abstract":"<div><div>Hashimoto's thyroiditis (HT) is one of the most prevalent endocrine disorders worldwide, and it can occur in people of all ages, including children. HT has a multifactorial pathogenesis and develops after a combination of gene regulation, environmental modifiers, and infection triggers. Various coamplifying feedback chronic inflammatory systems are involved in immune mechanisms, including oxidative stress, lymphocyte infiltration, and thyroid cell death. Furthermore, there is no effective treatment for HT at their roots. Thus, this review systematically summarizes and updates the existing etiology and pathogenesis, potential malignant transformation, emerging therapeutic drugs and animal model construction, making it more convenient for researchers to obtain effective information about HT and better explore potential strategies for short-term treatment of the disease.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 6","pages":"Article 103783"},"PeriodicalIF":9.2,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond circulating B cells: Characteristics and role of tissue-infiltrating B cells in systemic sclerosis","authors":"Mathilde Le Maître ,&nbsp;Thomas Guerrier ,&nbsp;Sébastien Sanges ,&nbsp;Aurélien Chepy ,&nbsp;Aurore Collet ,&nbsp;David Launay","doi":"10.1016/j.autrev.2025.103782","DOIUrl":"10.1016/j.autrev.2025.103782","url":null,"abstract":"<div><div>B cells play a key role in the pathophysiology of systemic sclerosis (SSc). While they are less characterized than their circulating counterparts, tissue-infiltrating B cells may have a more direct pathological role in tissues. In this review, we decipher the multiple evidence of B cells infiltration in the skin and lungs of SSc patients and animal models of SSc but also of other chronic fibrotic diseases with similar pathological mechanisms such as chronic graft versus host disease, idiopathic pulmonary fibrosis or morphea. We also recapitulate the current knowledge about mechanisms of B cells infiltration and their functions in tissues. Finally, we discuss B cell targeted therapies, and their specific impact on infiltrated B cells. Understanding the local consequences of infiltrating B cells is an important step for a better management of patients and the improvement of therapies in SSc.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 5","pages":"Article 103782"},"PeriodicalIF":9.2,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}